Economic  	Economic  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
of  	of  	 IN	I-NP
sublingual  	sublingual  	 FW	I-NP
immunotherapy  	immunotherapy  	 FW	I-NP
Allergic  	Allergic  	 FW	I-NP
rhinitis  	rhinitis  	 FW	I-NP
and  	and  	 CC	O
asthma  	asthma  	 NNS	B-NP
have  	have  	 VBP	O
a  	a  	 DT	O
very  	very  	 RB	O
high  	high  	 JJ	O
prevalence  	prevalence  	 NN	O
and  	and  	 CC	O
constitute  	constitute  	 VB	O
a  	a  	 DT	O
health  	health  	 NN	B-NP
problem  	problem  	 NN	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
relevant  	relevant  	 JJ	O
burden  	burden  	 NN	O
of  	of  	 IN	O
disease 	disease 	 NN	O
,  	,  	 ,	O
concerning  	concerning  	 VBG	O
medical  	medical  	 JJ	O
and  	and  	 CC	O
economical  	economical  	 JJ	B-NP
issues 	issues 	 NNS	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
treatments  	treatments  	 NNS	O
of  	of  	 IN	O
allergy 	allergy 	 NN	B-NP
,  	,  	 ,	O
specific  	specific  	 JJ	O
immunotherapy  	immunotherapy  	 NNS	B-NP
( 	( 	 -LRB-	O
IT 	IT 	 PRP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
the  	the  	 DT	O
capacity  	capacity  	 NN	O
to  	to  	 TO	O
favourably  	favourably  	 VB	O
alter  	alter  	 VB	O
the  	the  	 DT	O
natural  	natural  	 JJ	O
history  	history  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
both  	both  	 CC	O
during  	during  	 IN	O
and  	and  	 CC	O
after  	after  	 IN	O
its  	its  	 PRP$	O
performance 	performance 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
thus  	thus  	 RB	O
to  	to  	 TO	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
direct  	direct  	 JJ	O
and  	and  	 CC	O
indirect  	indirect  	 JJ	O
costs  	costs  	 NNS	O
of  	of  	 IN	O
allergic  	allergic  	 JJ	B-NP
rhinitis  	rhinitis  	 NN	I-NP
and  	and  	 CC	O
asthma 	asthma 	 NN	B-NP
.  	.  	 .	O
A  	A  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
studies  	studies  	 NNS	O
reported  	reported  	 VBD	O
a  	a  	 DT	O
cost  	cost  	 NN	B-NP
reduction  	reduction  	 NN	I-NP
for  	for  	 IN	O
traditional 	traditional 	 JJ	O
,  	,  	 ,	O
subcutaneous  	subcutaneous  	 VBD	B-NP
IT  	IT  	 PRP	O
( 	( 	 -LRB-	O
SCIT 	SCIT 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
analyzed  	analyzed  	 VBD	O
the  	the  	 DT	O
available  	available  	 JJ	O
studies  	studies  	 NNS	O
on  	on  	 IN	O
economic  	economic  	 JJ	B-NP
evaluation  	evaluation  	 NN	I-NP
of  	of  	 IN	I-NP
sublingual  	sublingual  	 JJ	I-NP
immunotherapy  	immunotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
SLIT 	SLIT 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
children  	children  	 NNS	O
and  	and  	 CC	O
adults 	adults 	 NNS	O
.  	.  	 .	O
Articles  	Articles  	 NNS	O
were  	were  	 VBD	O
retrieved  	retrieved  	 VBN	O
from  	from  	 IN	O
Medline  	Medline  	 NNP	B-NP
and  	and  	 CC	O
Embase  	Embase  	 NNP	B-NP
using  	using  	 VBG	O
the  	the  	 DT	O
terms  	terms  	 NNS	O
economic  	economic  	 JJ	B-NP
aspects 	aspects 	 NNS	I-NP
,  	,  	 ,	O
pharmacoeconomics 	pharmacoeconomics 	 NN	B-NP
,  	,  	 ,	O
cost  	cost  	 NN	B-NP
effectiveness 	effectiveness 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
sublingual  	sublingual  	 CD	B-NP
immunotherapy.  	immunotherapy.  	 CD	I-NP
18  	18  	 CD	O
articles  	articles  	 NNS	O
were  	were  	 VBD	O
found  	found  	 VBN	O
in  	in  	 IN	O
English  	English  	 JJ	O
language 	language 	 NN	O
,  	,  	 ,	O
7  	7  	 CD	O
studies  	studies  	 NNS	O
investigated  	investigated  	 VBD	O
the  	the  	 DT	O
economic  	economic  	 JJ	B-NP
advantage  	advantage  	 NN	I-NP
of  	of  	 IN	O
SLIT  	SLIT  	 NNP	O
over  	over  	 IN	O
standard  	standard  	 JJ	O
drug  	drug  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
in  	in  	 IN	O
subjects  	subjects  	 NNS	B-NP
with  	with  	 IN	O
respiratory  	respiratory  	 JJ	B-NP
allergy 	allergy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
2  	2  	 CD	O
of  	of  	 IN	O
them  	them  	 PRP	O
included  	included  	 VBD	O
a  	a  	 DT	O
comparison  	comparison  	 NN	O
of  	of  	 IN	O
costs  	costs  	 NNS	O
of  	of  	 IN	O
SCIT  	SCIT  	 NNP	B-NP
and  	and  	 CC	O
SLIT 	SLIT 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
data  	data  	 NNS	O
obtained  	obtained  	 VBD	O
provide  	provide  	 VB	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
SLIT  	SLIT  	 NNP	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
to  	to  	 TO	O
economic  	economic  	 JJ	B-NP
advantages  	advantages  	 NNS	I-NP
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
monetary  	monetary  	 JJ	B-NP
savings 	savings 	 NNS	I-NP
,  	,  	 ,	O
specifically  	specifically  	 RB	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
reduction  	reduction  	 NN	O
of  	of  	 IN	O
economic  	economic  	 JJ	B-NP
burden  	burden  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
studies  	studies  	 NNS	O
is  	is  	 VBZ	O
still  	still  	 RB	O
limited 	limited 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
available  	available  	 JJ	O
data  	data  	 NNS	O
support  	support  	 VBP	O
a  	a  	 DT	O
SLIT  	SLIT  	 NNP	O
effect  	effect  	 NN	O
on  	on  	 IN	O
sparing  	sparing  	 JJ	O
costs  	costs  	 NNS	O
for  	for  	 IN	O
respiratory  	respiratory  	 JJ	B-NP
allergy 	allergy 	 NN	I-NP
.  	.  	 .	O
